CD19-directed CAR T-cell therapy results in the depletion of endogenous B-cells and hypogammaglobulinemia, which lasts for an unclear duration and may impact long-term risk for infectious complications (19, 24). The gene discussed is CD19; the disease is Decreased circulating immunoglobulin concentration.